Cognitive impairment
Conditions
Interventions
None listed
Sponsors
Vandria SA
Eligibility
Sex/Gender
Male
Age
18 Years to 64 Years
Countries
France
Outcome results
None listed
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Feb 4, 2026